Fluticasone propionate and fluticasone furoate are both inhaled corticosteroid (ICS) medications used to manage inflammatory conditions, primarily asthma and chronic obstructive pulmonary disease (COPD) [1][2]. While they share the same active ingredient class, they differ in their chemical structure, potency, and duration of action, which influences their clinical use and dosing [3].
How are fluticasone propionate and fluticasone furoate chemically different?
The key difference lies in the ester side chain attached to the fluticasone molecule. Fluticasone propionate has a propionate ester, while fluticasone furoate has a furoate ester [3]. This structural variation affects how the drug binds to the glucocorticoid receptor and its lipophilicity, impacting its effectiveness and how long it remains in the lungs [4]. Fluticasone furoate is considered more potent than fluticasone propionate [3].
How do their potencies and dosing compare?
Fluticasone furoate is generally more potent, meaning a lower dose of fluticasone furoate can achieve a similar or greater therapeutic effect compared to fluticasone propionate [3]. This allows for once-daily dosing for fluticasone furoate in many treatment regimens, whereas fluticasone propionate is often dosed twice daily [5][6]. For example, in asthma management, higher potency ICS like fluticasone furoate may be preferred for patients requiring moderate-to-high dose ICS therapy [7].
What inhaled medications contain these ingredients?
Fluticasone propionate is the active ingredient in products such as Flovent HFA, Flovent Diskus, and Arnuity Ellipta [1]. Fluticasone furoate is found in medications like Breo Ellipta (in combination with vilanterol) and Arnuity Ellipta (as a standalone therapy) [2][8]. The specific brand name and delivery device can influence how the medication is administered and absorbed [9].
When are these medications typically prescribed?
Both medications are used for the maintenance treatment of asthma in patients aged four years and older [1][2]. They are also used for the long-term management of airflow obstruction in patients with COPD [1][2]. The choice between fluticasone propionate and fluticasone furoate often depends on the severity of the condition, the required dose, and the prescriber's preference, with fluticasone furoate sometimes being chosen for its enhanced potency and once-daily dosing convenience [7].
What are the potential side effects of fluticasone-based inhalers?
Common side effects for both fluticasone propionate and fluticasone furoate include upper respiratory tract infections, headache, nasopharyngitis, and oral candidiasis (thrush) [1][2]. Localized effects like hoarseness and throat irritation can also occur. Systemic side effects, though less common with inhaled use compared to oral corticosteroids, can include adrenal suppression, decreased bone mineral density, and growth retardation in children [10].
Are there any patented differences or exclusivity timelines?
The development of both fluticasone propionate and fluticasone furoate involved significant research and patent protection. As patents expire, generic versions can become available, potentially increasing accessibility and affordability. Information on specific patent statuses and expiry dates for these drugs and their formulations can be found through resources like DrugPatentWatch.com [11].
How do these medications interact with other treatments?
These inhaled corticosteroids are often used in combination with other respiratory medications, such as long-acting beta-agonists (LABAs) or long-acting muscarinic antagonists (LAMAs), to achieve optimal symptom control [7]. For instance, fluticasone furoate is available in combination products like Breo Ellipta with vilanterol, a LABA [2].
Sources:
[1] https://www.medicines.org.uk/emc/product/2977/smpc
[2] https://www.medicines.org.uk/emc/product/7678/smpc
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3097102/
[4] https://pubmed.ncbi.nlm.nih.gov/19729040/
[5] https://www.medicines.org.uk/emc/product/6667/smpc
[6] https://www.medicines.org.uk/emc/product/2847/smpc
[7] https://www.brit-thoracic.org.uk/document-library/guidelines-and-clinical-information/asthma/bts-sign-asthma-guideline-2019/
[8] https://www.medicines.org.uk/emc/product/7677/smpc
[9] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162968/
[10] https://www.nhs.uk/medicines/fluticasone-propionate-and-fluticasone-furoate/
[11] https://drugpatentwatch.com/